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Pim kinases are proto-oncogenes that are upregulated in a number of B cell cancers, including Epstein-Barr Virus (EBV) associated Burkitt's
lymphoma. They have also been shown to be upregulated in Kaposi sarcoma-associated herpes virus (KSHV) infected primary B cells. Most
cells in KSHV-associated tumors are latently infected and express only a small subset of viral genes, with KSHV latency associated nuclear
antigen (LANA) being constitutively expressed. LANA regulates the transcription of a large number of cellular and viral genes. Here, we show
that LANA upregulates transcription from the Pim-1 promoter (pPim-1) and map this activation to a region in the promoter located within the
sequence (−681 to +37). We show that LANA expressing cells can proliferate faster and are better protected from drug induced apoptosis. Since
transition through cell cycle check points and anti-apoptosis are functions associated with Pim-1, it is likely that higher Pim-1 expression in cells
expressing LANA is responsible, at least in part, for this effect. A Pim-1 phosphorylation site was also identified within the amino-terminal
domain of LANA. Using in vitro kinase assays, we confirmed that LANA was indeed a Pim-1 substrate, and the failure of Pim-1 to
phosphorylate LANA mutated at SS205/6RR identified this site as the specific serine residues phosphorylated by Pim-1. This report provides
valuable insight into yet another cellular signaling pathway subverted by KSHV LANA and suggests a contribution to KSHV related
oncogenesis.
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Kaposi sarcoma-associated herpesvirus (KSHV) or human
herpesvirus-8 has been shown to be the etiologic agent
associated with Kaposi sarcoma (Chang et al., 1994). It has
also been shown to be associated with pleural effusion
lymphoma (PEL) (Cesarman et al., 1995), a malignant B cell
lymphoproliferative disorder and with multicentric Castleman's
disease (MCD) (Soulier et al., 1995), a B cell proliferative
disorder characterized by polylymphadenopathy and multi-
organ involvement. All three of these disorders are associated
with a compromised immune state and/or AIDS. Recent
evidence suggests that herpesviruses may also play a role in⁎ Corresponding author. Fax: +1 215 898 9557.
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doi:10.1016/j.virol.2006.03.037the development of certain types of plasma-cell leukemias
(Hermouet et al., 2003). Like other herpes viruses, KSHV can
establish both latent and lytic infections. Most tumor cells,
however, are latently infected and express only a small subset of
viral antigens (reviewed in Cotter and Robertson, 2002). The
latency associated nuclear antigen (LANA) of KSHV is
constitutively expressed in all infected cells of KSHV-
associated lymphomas (reviewed in Verma et al., in press).
LANA has been shown to be critical for tethering of the
viral episome to host cell chromosomes (Ballestas et al., 1999;
Cotter et al., 2001; Krithivas et al., 2002; Piolot et al., 2001). It
has also been shown to be a potent transcriptional regulator of
both viral as well as host cell genes (Friborg et al., 1999;
Fujimuro and Hayward, 2003; Lim et al., 2000, 2001; Radkov
et al., 2000; Renne et al., 2001). Physical interaction with
upstream effectors is one mechanism by which LANA drives
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glycogen synthase kinase-3β (GSK-3β) and prevent it from
phosphorylating β-catenin, leading to the upregulation of β-
catenin-Tef/Lef responsive genes (Fujimuro and Hayward,
2003). Similarly, it binds unphosphorylated retinoblastoma
(Radkov et al., 2000) and the cAMP response element-binding
protein (CREB)-binding protein (CBP) (Lim et al., 2001),
thereby releasing transcription via the E2F and cAMP
transcription factors respectively. LANA can also directly
bind transcription factors and either drive or repress transcrip-
tion. It has been shown to bind and either synergistically
activate transcription factors AP-1 (An et al., 2004) and SP-1
(Verma et al., 2004) or repress transcription via mSin3
(Krithivas et al., 2000) and CREB (Lim et al., 2000, 2001).
Together, these transcription factors and upstream effectors
regulate a plethora of cellular genes, demonstrating the
importance of LANA in the complete subversion of cellular
gene expression by KSHV. Not surprisingly then, more than
400 genes were found to be significantly differentially
expressed following KSHV infection of CD34+ bone marrow
cells (Mikovits et al., 2001). Pim-2 was one of the 5 genes that
were found to be upregulated more than 3.5-fold in these cells.
Pim-1 was the first of Pim proteins identified, by proviral
tagging, as the preferred insertion site of murine leukemia virus
(MLV) in experiments designed to find genes involved in
tumorigenesis (Cuypers et al., 1984). The gene was shown to
encode for a serine/threonine kinase, and a number of
substrates have since been identified. There are two more
members in the Pim kinase family in humans, Pim-2 and Pim-
3. All three proteins are highly homologous and share common
functions. Pim kinases have been found to be overexpressed in
various lymphomas and leukemias. They are believed to play a
role in Burkitt's lymphoma (Gaidano and Dalla-Favera, 1993),
prostate cancer (Ayala et al., 2004; Dai et al., 2005), and
primary cutaneous large B cell lymphoma (Hoefnagel et al.,
2005). Pim-1 knockout mice, however, other than a reduced
body size, failed to demonstrate a distinct phenotype (Mikkers
et al., 2004). It has been proposed that Pim and c-myc can
cooperate in driving oncogenesis, and indeed, Emu Pim-1 and
L-myc or N-myc double transgenic mice had a more rapid
development and higher incidence of lymphoid malignancies
(Verbeek et al., 1991). Pim kinases are upregulated in Epstein
Barr Virus (EBV) or Human Herpes Virus-4 infected cells and
in turn enhance the activity of EBV transcriptional activator
EBNA2 (Rainio et al., 2005).
Pim-1 promotes proliferation by easing transition through
both G1/S and G2/M cell cycle checkpoints. It helps transit
through G1/S by phosphorylation of Cdc25A, a positive
regulator of G1/S transition (Mochizuki et al., 1999) and by
phosphorylation and inactivation of p21 (Wang et al., 2002), a
cyclin-dependent kinase inhibitor. Transit through G2/M is
mediated by phosphorylation and activation of Cdc25C, a cdc2
activator (Bachmann et al., 2004), coordinated with phosphor-
ylation and deactivation of CTAK1, a Cdc25C inhibitor
(Bachmann et al., 2004). Pim-1 also associates with and
phosphorylates the nuclear mitotic apparatus (NuMA) protein
(Bhattacharya et al., 2002). A kinase dead version of Pim-1failed to bind NuMA, promoted apoptosis and chromosomal
instability (Bhattacharya et al., 2002). Pim-1 has been shown to
promote cell survival mainly by phosphorylating and inactivat-
ing proapoptotic Bad (Aho et al., 2004; Yan et al., 2003). Given
that the nature of KSHV-associated B cell disorders is mainly
proliferative, it is possible that overexpression of Pim kinases in
infected cells contributes to their higher proliferation and
survival rate.
In this report, we confirm that Pim-1 is indeed upregulated in
KSHV-positive cell lines and attribute this upregulation to the
expression of LANA in these cells. We also show that LANA is
able to activate transcription from the Pim-1 promoter.
Moreover, LANA expressing cells, along with overexpressing
Pim-1, proliferate faster and in the presence of apoptosis
inducing drugs have greater survivability, both functions
associated with Pim-1. A Pim-1 consensus site was also
identified within the N-terminus of LANA that was phosphor-
ylated by Pim-1 in vitro. Thus, these results identify another
signaling pathway exploited by KSHV and a potential
therapeutic target for intervention in KSHV-associated
malignancies.
Results
LANA expressing cells have higher Pim-1 levels
Total cellular RNA was isolated from HEK-293 cells stably
expressing KSHV LANA, and cDNA was generated using a
First Strand synthesis kit. RNA from cells similarly selected
but transfected with a control vector was used as control. A
microarray screen using this cDNA was performed to identify
changes in gene expression in LANA expressing cells. Pim-1,
closely followed by Pim-2, was found to be the most highly
upregulated oncogene when compared to the control. To
verify this result, we compared the Pim-1 transcript levels in
KSHV-negative B cell lymphoma cell lines to that in KSHV-
positive body cavity based-lymphoma derived cell lines. The
ratio of Pim-1 transcript levels in KSHV-positive cells to that
in KSHV-negative cells ranged from ∼6 (BC-3: DG-75) to
∼50 (BCBL-1: Loukes) (Fig. 1A). We also confirmed the
microarray data using qPCR and compared the transcript
levels of Pim-1 in LANA expressing cells and control cells
transfected with vector alone. Cells expressing LANA had
∼3-fold higher levels of Pim-1 transcripts compared to
control cells (Fig. 1B). This result agrees nicely with our
previously done microarray screen (data not shown). The fact
that the fold difference in Pim-1 transcripts between KSHV-
positive and KSHV-negative cells is much higher than that
seen with LANA expression alone, points to additional
mechanisms for upregulation/stabilization of Pim-1 in these
cells. A candidate mechanism for this upregulation of Pim-1
may be via vIL-6 stimulation of Pim-1 transcription. IL-6 has
been shown to be a potent upregulator of Pim-1 levels via the
STAT pathway (Hirano et al., 2000; Narimatsu et al., 2001;
Rahman et al., 2001). While vIL-6 is not expressed in latently
infected cells, a fraction of primary effusion lymphoma cells
of the BCP-1 cell line stain positive for the protein in culture
Fig. 1. Pim-1 transcript is upregulated in LANA expressing cells. Total RNA
was isolated from 10 million cells (A: KSHV-positive or negative, B: LANA or
vector stable) using Trizol reagent. 5 μg of RNAwas used in the Superscript first
strand synthesis system to construct cDNA. Real-time PCR was performed
using a SYBR green quantitative PCR kit with β-actin as standard. The PCR
data are expressed as fold change relative to cells expressing lowest levels of the
transcript as calculated by the ΔΔCt method.
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responsible in part for this large upregulation of Pim-1.
LANA enhances transcriptional activity of the Pim-1 promoter
in epithelial cells and B cells
KSHV LANA has been shown to regulate transcription from
various promoters by interacting with transcription factors or
upstream effectors known to regulate these promoters (Fuji-
muro and Hayward, 2003; Krithivas et al., 2000; Lan et al.,
2004; Lim et al., 2000; Radkov et al., 2000; Verma et al., 2004).
Since Pim-1 transcript level was elevated in cells stably
expressing LANA, we decided to investigate if LANA could
increase transcription from the Pim-1 promoter. The region
−1700 to +37 of the Pim-1 promoter (Borg et al., 1999) was
cloned into pGL3 Basic, a luciferase reporter construct.
HEK-293Tor DG-75 cells were cotransfected with the Pim-1
promoter construct and increasing amounts of the LANA
expression construct. Empty LANA vector was used to adjust
for the differences in total DNA being transfected. A LANA
dose dependent increase in luciferase activity was observed in
transfected cell lysates, independent of cell type (Figs. 2A, B).
This result shows that elevated Pim-1 transcript level in LANA
expressing cells is due to LANA mediated upregulation of
transcription from the Pim-1 promoter. Western blots of thelysates show that transfection of increasing amounts of LANA
expression construct did indeed result in increasing amounts of
LANA protein expression. Expectedly, the β-actin expression
remained unchanged for each transfection.
Examination of the promoter sequence revealed several
transcription factor binding sites, of which the ones displaying
greater than 95% homology are shown (Fig. 2C). It is of note
that a number of these transcription factors have been shown to
be regulated by LANA (An et al., 2004; Radkov et al., 2000;
Verma et al., 2004). We also created two deletion mutants of the
promoter in one of which all elements short of the interferon-γ
(IFN-γ) activation site (GAS) (Kanno et al., 1993; Khan et al.,
1993) were deleted and, in the other, all elements short of and
including GAS were deleted (Fig. 2C). The GAS site has been
shown to be responsible for IFN-γ mediated upregulation of
Pim-1 (Yip-Schneider et al., 1995). To determine, if LANA
exerted its enhancing effect on the Pim-1 promoter via this GAS
site, cells were transfected with either the full-length promoter,
or one of the two deletion mutants in the presence or absence of
LANA (Fig. 2C). Similar fold upregulation was observed for
the full-length promoter, promoter deleted short of the GAS site
and that in which the GAS site was also deleted (Fig. 2D). The
−681 to +37 promoter sequence contains an E2F element with
100% homology and two SP1 regulatable elements with 97%
and 95% homology respectively. LANA has been shown to
regulate transcription of other promoters which contain these
sites (E2F (Radkov et al., 2000), SP1 (Verma et al., 2004)) by
modulating the activities of these transcription factors. It is
noteworthy, that the baseline activity of the promoter was higher
for the shortest promoter length (−681 to +7) compared to that
for the full-length promoter. The baseline activity of the
intermediate promoter length (−1140 to +7), on the other hand,
was lower than the effect of no promoter sequence at all
(background level) (Fig. 2D). This result points to the presence
of a strong inhibitory element between nucleotides −1140 and
−681 of the Pim-1 promoter.
LANA expressing cells have enhanced proliferation
Since LANA expressing cells express higher levels of Pim-1,
and Pim-1 has been associated with faster progression through
both G1/S and G2/M cell cycle checkpoints (Bachmann et al.,
2004; Barre et al., 2003; Bhattacharya et al., 2002; Wang et al.,
2002), it is possible that LANA positive cells have enhanced
proliferation. To test this, we used BJAB cell lines stably
expressing either DsRed-LANA or DsRed (vector control).
These cell lines were stably transfected with vectors expressing
shRNA for either Pim-1 or Firefly Luciferase (as a control).
shRNA directed against Pim-1 resulted in an 8-fold reduction in
levels of Pim-1 transcript, when compared to the control shRNA
(Fig. 3A). To assess the effect of LANA and Pim-1 on
proliferation, the cells were stained with CFSE and assayed to
determine their comparative proliferation rate 72 h post-
staining. As expected, in the cell lines transfected with the
control shLuc (shFirefly Luciferase), the cells expressing
LANA proliferated to a greater degree than control cells
(Figs. 3B, C). Expression of Pim-1 shRNA had a pronounced
Fig. 3. Cells expressing LANA proliferate faster. BJAB cells, stably expressing either DsRed or DsRed-LANAwere transfected with constructs for shPim-1 or shLuc
and then selected for stable expression with Puromycin. (A) Following selection, cells were assayed for levels of Pim-1 transcript using real-time PCR, with β-actin as
standard. The PCR data are expressed as fold change relative to cells expressing lowest levels of the transcript as calculated by theΔΔCt method. (B) At the same time,
cells were stained with CFSE and incubated in medium supplemented with 0.1% bovine growth serum. Cells were assayed for degree of proliferation 72 h post-
staining using flow cytometry. Histogram shows CFSE signal in, DsRed+shLuc, DsRed-LANA+shLuc, DsRed+shPim-1 and DsRed-LANA+shPim-1, cells 72 h
post-staining. (C) Geometric mean of fluorescence at the time of assay is shown as a means of quantifying the degree of proliferation in various samples.
Fig. 2. LANA upregulates Pim-1 promoter activity. (A and B) Either HEK-293T cells or DG-75 cells were cotransfected with the Pim-1 promoter and increasing
amounts of pA3M-LANA. (C) Schematic of the full-length Pim-1 promoter and two deletion mutants with transcription factor binding sites marked. (D). HEK-293T
cells were transfected with either the full-length Pim-1 promoter or its deletion mutants with or without pA3M-LANA. (A, B and D) The cells were harvested 36 h later
and tested for luciferase activity. Values are shown normalized to the baseline reporter activity in the absence of LANA. Western blots show amounts of transfected
LANA and endogenous β-actin in harvested cell lysates.
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well as the control cells, confirming the previously demonstrat-
ed importance of Pim-1 in cell proliferation (Bachmann et al.,
2004; Barre et al., 2003; Bhattacharya et al., 2002; Wang et al.,
2002). Interestingly, even after transfection with Pim-1 shRNA
(Grunweller et al., 2003), LANA expressing cells continued to
proliferate faster than control cells showing that elevation of
expression of Pim-1 was not the only mechanism by which
LANA was enhancing cell proliferation (Figs. 3B, C).
LANA expressing cells are protected from apoptosis
Pim-1 has also been shown to have an anti-apoptotic effect,
mainly due to its phosphorylation and deactivation of
proapoptotic BAD (Aho et al., 2004; Yan et al., 2003). We
tested to see if LANA expressing cells were able to survive
better in the presence of proapoptotic drugs. Staurosporine, a
pan-kinase inhibitor (Kruman et al., 1998), has been shown to
mediate cells death in various cell types. DsRed-LANA or
vector transfected cells were incubated in growth medium
containing 2 μM Staurosporine. Cells were assayed for
induction of cell death 24 h post-exposure. LANA expressing
cells were significantly less prone to induction of apoptosis
upon exposure to Staurosporine when compared to control cells
(Fig. 4).
Pim-1 kinase phosphorylates LANA in vitro
The preferred site for Pim-1 phosphorylation has been
identified as K/R-K/R-R-K/R-L-S/T-X, where X is an amino
acid residue with a small side chain (Palaty et al., 1997).
Examination of the LANA amino acid sequence revealed the
existence of a Pim-1 phosphorylation site (AAs 200–206),
which matches exactly one of the permutations of the identified
preferred site (Fig. 5A). To act as a negative control, we
generated a Pim-1 construct in which the lysine at position 67 is
changed to methionine. This single point mutation (K67M),
which disrupts the ATP binding site, rendered the kinase dead in
terms of its phosphorylation activity (Wang et al., 2002).
Autophosphorylation was observed in the reaction mixturesFig. 4. Cells expressing LANA are protected for drug induced apoptosis. Cells, expr
with Staurosporine (2 μM). Cells were assayed for apoptosis associated DNA fragm
DsRed and DsRed-LANA cells 24 h post-exposure to Staurosporine. Plot shows qucontaining Pim-1, but not Pim-1-K67M, showing that the
mutation had indeed rendered the enzyme inactive (Figs. 5B,
compare lanes 2 and 4 with lanes 3 and 5). Immunoprecipitated
Pim-1, but not Pim-1-K67M, phosphorylated a GST fusion
LANA 1–340, which contains the putative consensus sequence
(Fig. 5B, compare lanes 4 and 5). The same result was obtained
when full-length immunoprecipitated LANA was used as a
substrate (Fig. 5C, compare lanes 4 and 5). Coomassie stained
GST fusion protein (Fig. 5B), and Western blots with 10% of
the immunoprecipitated proteins are shown to indicate levels in
each reaction mixture (Figs. 5B, C). Light chain of the IgG
added for immunoprecipitation is shown to indicate that equal
amount of antibody was added for each immunoprecipitation
(Figs. 5B, C).
Phosphorylation of LANA occurs at the Pim-1 consensus site
To verify if phosphorylation of LANA by Pim-1 was
occurring at the identified Pim-1 consensus site, we generated
LANA constructs in which the serines at positions 205 and 206
were changed to arginines. An in vitro kinase assay, done to test
if Pim-1 was able to phosphorylate this mutated form of LANA
(LANA SS205/6RR), showed robust phosphorylation of GST
fused LANA 1–340 (positive control) and no phosphorylation
of GST fused LANA 1–340 SS205/6RR (Fig. 6A, compare
lanes 4 and 5). The same result was observed, when full-length
immunoprecipitated LANA and LANA SS205/6RR were used
as substrates (Fig. 6B, compare lanes 4 and 5). Based on these
results, it is most likely that Pim-1 phosphorylation occurs at
either one or both of the serines at positions 205 and 206, and
that these are the predominant Pim-1 phosphorylation sites in
full-length LANA.
Pim-1 binds to the C-terminus of LANA
Since phosphorylation likely requires a physical interaction
between LANA and Pim-1, we decided to identify the region of
LANA that was binding to Pim-1. 35S labeled in vitro translated
LANA 1–340 or LANA 762–1162 was tested for binding to
GST fused Pim-1. The amino-terminus of LANA contains theessing either DsRed or DsRed-LANA, were incubated in medium supplemented
entation 24 h post-introduction of the drugs. Histograms show DNA content of
antification of apoptotic cells at the time of assay.
Fig. 5. Pim-1 phosphorylates LANA in vitro. (A) Amino acid sequence of LANA indicating the Pim-1 consensus site. The ‘X’ in the Pim-1 consensus sequence is any
amino acid residue with a small side chain. The possible Pim-1 phosphorylation sites are underlined. (B and C) HEK-293T cells were transfected with expression
constructs for Pim-1, Pim-1 K67M (kinase dead Pim-1), full-length LANA, or the vector as control. After 36 h, protein immunocomplexes were captured and assayed
for in vitro kinase activity toward either (B) GST LANA 1–340 or (C) full-length immunoprecipitated LANA.Western blotting shows 10% of the immunoprecipitated
protein. Coomassie stain shows level of GST fusion protein added. Light chain of the IgG added for immunoprecipitation is shown to indicate that equal amount of
antibody was added for each immunoprecipitation. Quantification of kinase activity was done with ImageQuant software (Molecular Dynamics) and normalized to
level of LANA phosphorylation in the absence of Pim-1.
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this in vitro assay (Fig. 7). This suggests that the phosphory-
lation event itself may require only a transient interaction with
the amino-terminal domain or that a third as yet to be identified
molecule maybe involved in recruiting Pim-1 to the amino-
terminus of LANA. Interestingly, the carboxy-terminus of
LANA did associate with GST-Pim-1 and suggests a possible
role for the carboxy-terminus, either as a stabilizing component
or as a recruitment arm that brings Pim-1 in position to the
amino terminal domain for phosphorylation (Fig. 7).
Discussion
In this report, we demonstrate that KSHV LANA transcrip-
tionally upregulates the Pim-1 kinase proto-oncogene (Fig. 8).
We show that the possible consequences of this upregulation are
increased proliferation and better survival of LANA expressing
cells. This might in part explain the hyperproliferative
phenotype in KSHV-associated disorders.
We mapped the region of the Pim-1 promoter most likely to
contain sequences that are positively regulated by LANA and,
in the process, identified a length of the promoter that contains a
strong inhibitory sequence. A previously described inhibitory
sequence lies between −336 and −104 bp (Borg et al., 1999).The inhibitory sequence identified by us is apparently different
and lies between −1140 and −681 bp. Further characterization
of this sequence should provide interesting insights into the
regulation of Pim-1, but it is beyond the scope of this initial
study.
We have confirmed previously shown results that LANA
transfected cells proliferated faster (Fujimuro et al., 2003) and
were more resistant to apoptosis (Friborg et al., 1999; Katano et
al., 2001) than control cells. Knockdown of Pim-1 using Pim-1
shRNA had a marked effect on proliferation of both LANA
expressing cells as well as control cells. Despite this, LANA
expressing cells continued to proliferate faster than control
cells, albeit to a slightly lesser degree than when they were
transfected with control luciferase shRNA. Fujimuro et al.
attributed faster proliferation of LANA transfected cells to
stabilization of β-catenin and upregulation of transcription from
Tef/Lef responsive promoters, particularly c-Myc and Cyclin-D.
Friborg et al. and Katano et al., showed that LANA expressing
cells were able to resist apoptosis due to LANA's association
with p53 and the subsequent down regulation of p53 mediated
transcription (Friborg et al., 1999; Katano et al., 2001). While
these arguments deserve merit, multiple studies have shown that
Pim-1 can drive proliferation by helping to bypass both of the
major cell cycle checkpoints (Bachmann et al., 2004; Barre et
Fig. 6. Phosphorylation of LANA by Pim-1 occurs at the Pim-1 consensus site. (A and B) HEK-293T cells were transfected with expression constructs for Pim-1, full-
length LANA, full-length LANA SS205/6RR (mutated at Pim-1 consensus site). After 36 h, protein immunocomplexes were captured and assayed for in vitro kinase
activity toward either (A) GST LANA 1–340 SS205/6RR or (B) full-length immunoprecipitated LANA SS205/6RR. Either GST-LANA 1–340 or full-length
immunoprecipitated LANA served as corresponding positive controls. Western blotting shows 10% of the immunoprecipitated protein. Coomassie stain shows level of
GST fusion protein added. Light chain of the IgG added for immunoprecipitation is shown to indicate that equal amount of antibody was added for each
immunoprecipitation. Quantification of kinase activity was done with ImageQuant software (Molecular Dynamics) and normalized to level of LANA phosphorylation
in the absence of Pim-1.
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also prevent apoptosis via the Bcl-2 pathway by phosphorylat-
ing proapoptotic BAD (Aho et al., 2004). Our results suggest
that LANA mediates proliferation and ensures survival in
multiple ways, and that Pim-1 is another one of these pathways
that is usurped by LANA. Previous reports have also indicated
that the Pim-1 and c-Myc pathways cooperate to promote
lymphomagenesis (Verbeek et al., 1991). In this context, our
results of Pim-1 upregulation along with previous reports of c-
Myc upregulation (Kaaya et al., 2000) is likely to enhance our
knowledge in terms the mechanisms of KSHV mediated
oncogenesis.
We also found that LANA was a substrate for Pim-1
mediated phosphorylation. Using site directed mutagenesis, we
were able to identify the probable site for this phosphorylation.
However, the exact consequence of this phosphorylation on the
viral life-cycle remains to be elucidated. Initial tests to see if
LANA mutated at the Pim-1 phosphorylation site failed to
activate transcription from the Pim-1 promoter showed that
there was no difference between wt-LANA and LANA SS205/
6RR in this regard (data not shown). Phosphorylation of LANA
by Pim-1, therefore, may not be strictly required for the
upregulation of Pim-1 transcription. Also, levels of proliferation
and drug induced apoptosis in LANA SS205/6RR transfected
cells were found to be no different from those observed with wt-
LANA (data not shown).
Phosphorylation of LANA by two other kinases has been
reported in the past. GSK-3β has been shown to phosphor-ylate LANA at multiple sites in its N-terminus (Fujimuro et
al., 2005) LANA, thus acting as a substrate for GSK-3β,
sequesters GSK-3β's ability to phosphorylate other sub-
strates. In this manner, it prevents degradation of β-catenin
and releases β-catenin mediated transcription (Fujimuro et
al., 2003). Interestingly, β-catenin activates the transcription
of c-myc, which cooperates with Pim-1 in regulation of cell
cycle and survival. The other kinase that phosphorylates
LANA is recruited by Ring3, and phosphorylates LANA on
its carboxy-terminus (Viejo-Borbolla et al., 2005). The
identity of the kinase and the importance of this phosphor-
ylation are yet to be elucidated. Another explanation for
LANA acting as a substrate for Pim-1 could be the possible
stabilization of Pim-1 in its bound form to LANA. Pim-1 is
a highly unstable protein, with a reported intracellular half-
life of approximately 15 min to 2 h (Shay et al., 2005). Its
de-phosphorylation by PP2A leads to its degradation (Los-
man et al., 2003). It is possible that binding to LANA
shields the de-phosphorylation site of Pim-1 and therefore
prevents its degradation. These hypotheses are under current
investigation in our laboratory.
Materials and methods
Plasmids, antibodies, and cell lines
pA3M-LANA expresses the full-length protein with 3
carboxy-terminal myc tag as described previously (Cotter and
Fig. 7. Pim-1 associates with the carboxy-terminus of LANA. 35S labeled LANA
1–340 and LANA 762–1162 were prepared using a TNT T7 quick-coupled
transcription/translation system. 10% of the in vitro translated protein was set
aside to be used as input control. The remaining translated protein was diluted
with binding buffer, precleared with glutathione-sepharose beads and rotated
overnight with either GST (control) of GST fused Pim-1. Proteins were pulled
down with glutathione-sepharose beads, washed 5-times with binding buffer and
resolved in an SDS-PAGE. Protein levels in each lane were quantified with
ImageQuant software (Molecular Dynamics) and normalized to level of that
associated with GST control.
Fig. 8. Schematic of the interaction between KSHV LANA and serine/threonine
kinase Pim-1. The schematic shows that LANA upregulates Pim-1 transcription
via one of the transcription factor sites downstream of the GAS element,
contributing to an increase in proliferation and enhanced survival of LANA
expressing cells. LANA, in turn, is a substrate for of Pim-1, and is
phosphorylated at S205 and/or S206. The consequence of LANA phosphory-
lation by Pim-1 remains to be determined but is likely to result in enhanced
proliferation of KSHV-positive cells.
25B.G. Bajaj et al. / Virology 351 (2006) 18–28Robertson, 1999). The pA3M-Pim-1 construct was generated
by PCR amplification and cloning into the pA3M vector,
using pEGFP-Pim-1 (kindly provided by Dr. Nancy Magnu-
son) as a template(Bhattacharya et al., 2002). Pim-1 K67M,
a kinase dead version of Pim-1 mutated at the ATP binding
pocket (Wang et al., 2002), was generated by site directed
mutagenesis using pA3M Pim-1 as a template. pA3M-LANA
SS205/6RR, mutated at the preferred site for Pim-1
phosphorylation (Palaty et al., 1997), was generated by site
directed mutagenesis using pA3M LANA as a template. The
pGEX2TK-LANA 1–340 construct encodes for a truncated
amino-terminal LANA fused to GST and pGEX2TK-LANA
1–340 SS205/6RR construct was cloned by PCR amplifica-
tion using pA3M-LANA SS205/6RR as a template. The
pGEX2T-Pim-1 construct encodes for full-length Pim-1 fused
to GST and was provided by Dr Nancy Magnuson (Wang et
al., 2002). The full-length Pim-1 promoter was cut out of
pBS SK+ pPim-1 (provided by Dr Nancy Magnuson) by
restriction digest and cloned into pGL3 Basic. Truncations of
the Pim promoter were generated using unique restriction
sites for MscI (-1140) and AatII (-681) along with the KpnI
site in the MCS of the vector. The pDsRed1-N1-LANA and
pDsRed1-N1-LANA SS205/6RR constructs encode for the
full-length protein tagged with DsRed at its carboxy-
terminus. Pim-1 shRNA was cloned into the pSiren RetroQ
Tet-P vector (Clontech Laboratories, Mountain View, CA).
pSiren RetroQ Tet-P shFirefly Luciferase (Clontech) wasused as a control. The Pim-1 target sequence 5′-GUGUA-
CUUUAGGCAAAGGG-3′ has been described previously
(Grunweller et al., 2003). Integrity of all generated clones
was confirmed by sequence analysis. Mouse monoclonal
anti-myc 9E10 was generated from a hybridoma and rabbit
polyclonal anti-β-actin was purchased from Cell Signaling
Technologies (Beverly, MA). Infrared 700-tagged anti-mouse
and anti-rabbit secondary antibodies were from Invitrogen
(Carlsbad, CA) and infrared 800-tagged anti-mouse and anti-
rabbit secondary antibodies were purchased from Rockland
(Gilbertsville, PA).
HEK-293 cells are human embryonic kidney cells
transformed with sheared adenovirus 5 DNA (Graham et
al., 1977). HEK-293T cells are HEK-293 cells that stably
express the SV40 large-T antigen. Louckes (van Santen et al.,
1981) and DG-75 (Ben-Bassat et al., 1977) are Burkitt's
lymphoma cell lines that are both KSHV and EBV negative.
BCBL-1 (Renne et al., 1996) and BC-3 (Arvanitakis et al.,
1996) are KSHV-positive, but EBV negative, body cavity-
based lymphoma derived cell lines. HEK-293 and HEK-293T
cells were grown in Dulbecco's modified Eagle's medium
supplemented with 5% bovine growth serum, 50 U/ml
penicillin, 50 μg/ml streptomycin, and 2 mM L-glutamine.
All B cell lines were grown in RPMI 1640 medium
supplemented with 7% bovine growth serum, 50 U/ml
penicillin, 50 μg/ml streptomycin and 2 mM L-glutamine.
Transfection
HEK-293T and DG-75 cells were transfected by electro-
poration with a Bio-Rad Gene Pulser II electroporator. Ten
million cells harvested in exponential phase were collected,
washed in phosphate-buffered saline and resuspended in
400 μl of appropriate medium without serum containing DNA
for transfection. Resuspended cells were transferred to a 0.4-
cm gap cuvette, and electroporation was done at 975 μF and
210 V or 220 V for 293T and DG-75 cells respectively.
Transfected cells were transferred to a 100-mm Petri dish
containing 10 ml of complete medium and incubated at
37 °C. Cells were harvested 24 to 36 h post-transfection for
analysis.
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Transfected HEK-293T cells were harvested, washed with
ice-cold PBS and lysed in 1.5 ml ice-cold RIPA buffer (0.5%
NP-40, 10 mM Tris [pH 7.5], 2 mM EDTA, 150 mM NaCl,
supplemented with protease and phosphatase inhibitors). Cell
debris was removed by centrifuging (18000 × g, 10 min and
4 °C) and transferring the supernatant to a fresh tube. Lysates
were precleared by rotating (1 h, 4 °C) with a mix of normal
mouse serum, protein-A and protein-G beads and then rotated
with 1 μl of 9E10 myc-reactive ascites fluid overnight at 4 °C.
Immune complexes were captured with a 1:1 mixture of protein-
A and protein-G sepharose beads, pelleted and washed 2× with
ice cold RIPA buffer.
For Western blots, harvested cells were lysed with 300 μl of
reporter lysis buffer (Promega, Inc., Madison, WI), and 40 μl of
this lysate was used. In the case of immunoprecipitated proteins,
10% of the IP was used for Western blots. Briefly, lysates or IP
complexes were boiled in Laemmli buffer, fractionated by SDS-
PAGE and transferred to a 0.45 mm nitrocellulose membrane.
The membranes were then probed with anti-myc or anti-β-actin
antibodies followed by incubation with appropriate infrared-
tagged secondary antibodies and viewed on an Odyssey imager
(LiCor Inc., Lincoln, NE).
Real-time quantitative PCR
Total RNA from cells was isolated using Trizol reagent
(Invitrogen) following the manufacturer's instructions. cDNA
was generated using a Superscript II RT kit (Invitrogen)
following the manufacturer's instructions. The specific primers
used for Pim-1 (Kim et al., 2005) and β-actin (Kuppers et al.,
2005) have been described previously. The cDNA was
amplified using SYBR green real-time mastermix (MJ
Research Inc., Waltham, MA), 400 nM each primer, and
1 μl of the cDNA product in a total volume of 20 μl. The PCR
protocol used was 30s at 95 °C, 30s at 50 °C, and 30 s at
72 °C, followed by a final extension of 7 min at 72 °C. Each
cycle was followed by a plate read at 78 °C. A melting curve
analysis was performed to verify the specificity of the
products, and the values for the relative quantitation were
calculated by the ΔΔCt method. The experiment was
performed in triplicate.
Reporter assays
Ten million HEK-293T or DG-75 cells were cotransfected
with 5 μg Pim-1 promoter construct and the indicated amounts
of pA3M-LANA. The differences in amount of the LANA
construct were made up with pA3M vector to keep the total
amount of transfected DNA constant. Twenty-four hours post-
transfection, the cells were harvested, washed with PBS, and
lysed in 300 μl of reporter lysis buffer. A 40-μl aliquot of the
lysate was transferred to a 96-well plate. Luciferase activity was
measured using an LMaxII384 luminometer (Molecular
Devices, Sunnyvale, CA) by injecting 25 ml of luciferase
substrate into each well and integrating the luminescence for 10spost-injection. Some of the lysate was used for Western blots as
described above.
Proliferation assays
BJAB cell lines stably transfected with pDsRed1-N1-LANA
or pDsRed1-N1 (vector control) have been described previously
(Si and Robertson, 2006). These cell lines were transfected with
either a vector expressing shPim-1 or shLuc. Transfected cells
were maintained in 200 μg/ml G418 and selected with 2 μg/ml
Puromycin for ∼20 days. DsRed and DsRed-LANA expression
was monitored by fluorescence microscopy. At the end of the
selection period, the cells were transferred to growth medium in
the absence of drugs and used for proliferation assays. Briefly,
the cells were stained with carboxyfluorescein diacetate
succinimidyl ester (CFSE; Invitrogen) as per the manufacturer's
recommendation. The cells were incubated in culture media
supplemented with 0.1% bovine growth serum and assayed at
72 h post-staining using a flow cytometer (FACS Calibur,
Becton Dickinson, Franklin Lakes, NJ).
Apoptosis assays
Transfected cells were incubated in growth medium for
approximately 24 h to allow for sufficient levels of transgene
expression. The cells were then incubated in regular culture
media supplemented with 2 μM Staurosporine to induce
apoptosis. For DNA content analysis, cells were fixed with
4% buffered formalin, permeabilized with 0.05% Triton-X in
PBS and stained with propidium iodide (PI; Invitrogen)
containing RNAse-A.
In vitro kinase assays
Immunoprecipitated protein complexes bound to protein-A/
G beads and GST fusion proteins bound to glutathione-
sepharose beads were combined in pairs for to make appropriate
reaction mixtures. The beads were pelleted and washed once
with ice cold Pim kinase buffer (20 mM PIPES [pH 7.0], 5 mM
MnCl2 and 7 mM β-mercaptoethanol supplemented with
protease and phosphatase inhibitors) (Bachmann et al., 2004).
The reaction beads were pelleted and resuspended in 40 μl Pim
kinase buffer supplemented with 10 μM cold ATP and 10 μCi
32P γ-ATP. The reaction was incubated at 30 °C for 30 min and
stopped by boiling in Laemmli buffer for 10 min. Labeled
proteins were resolved by SDS-PAGE and detected using
Phosphor Imager Storm 860 (GE Healthcare, Waukesha, WA).
Images were quantified using ImageQuant software.
GST pull-down assays
GST fusion Pim-1 was purified from bulk Escherichia coli
cultures following induction with isopropyl-β-D-thiogalacto-
pyranoside (IPTG) as described previously (Cotter and Robert-
son, 2000). In vitro translation of 35S-labeled amino and
carboxy-termini of LANA was done with the TNT T7 quick-
coupled transcription/translation system (Promega Corporation,
27B.G. Bajaj et al. / Virology 351 (2006) 18–28Madison, WI) according to the manufacturer's instructions. Ten
percent of the translated product was set aside to serve as input
control. For GST pull-down assays, the remaining in vitro
translated protein was diluted in 500 μl binding buffer (0.1%
NP-40, 0.5 mM dithiothreitol [DTT] and 10% glycerol in 1×
phosphate-buffered saline supplemented with protease and
phosphatase inhibitors), and precleared with glutathione-sephar-
ose beads. Samples were then rotated overnight at 4 °C with
either GST control or GST-Pim-1 fusion protein bound to
glutathione-sepharose beads. Beads were pelleted and washed
with binding buffer 5 times. The samples were boiled in
Laemmli buffer for 10 min, resolved by SDS-PAGE and
detected using Phosphor Imager Storm 860.
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